DOGS · Condition guide
Canine osteosarcoma: real veterinary cases
Osteosarcoma is an aggressive bone cancer that most commonly affects large and giant-breed dogs, typically over 7 years of age. The classic presentation is persistent, often severe lameness in a forelimb (wrist or shoulder) without a clear trauma history. The tumour destroys bone from the inside out and is painful long before it's obvious on the outside.
Outcomes have improved meaningfully over the last two decades. Amputation alone resolves the pain but median survival is short; amputation plus chemotherapy (typically carboplatin) extends median survival to around 10-12 months. Limb-sparing surgery and stereotactic radiation are options in some referral centres. The earlier the diagnosis, the more options are on the table.
What vets typically check for
- Radiographs of the painful site — classic findings: cortical lysis, sunburst periosteal reaction.
- Chest radiographs (3 views) or ideally CT to stage for pulmonary metastasis.
- Bloodwork including alkaline phosphatase (elevated ALP is a poor prognostic indicator).
- Bone aspirate or biopsy to confirm diagnosis when imaging is ambiguous.
- Treatment: amputation + carboplatin (or doxorubicin) is the most common protocol.
Not a replacement for veterinary care. Use this to walk into the conversation prepared, not to self-diagnose.
Real cases from the veterinary literature
Peer-reviewed reports our semantic search surfaces for Osteosarcoma. Click into any case for the full abstract — or run a personalised search with your pet's exact details.
- Alternating carboplatin and doxorubicin as adjunctive chemotherapy to amputation or limb-sparing surgery in the treatment of appendicular osteosarcoma in dogs.
Journal of veterinary internal medicine · 2004 · United States
In this study, 32 dogs with a type of bone cancer called appendicular osteosarcoma (which affects the limbs) underwent surgery, either amputation or a limb-sparing procedure, and then received additional chemotherapy. The chemotherapy involved alternating treatments with two drugs, carboplatin and doxorubicin, given every three weeks for a total of three cycles. The results sho
- Canine Osteosarcoma Treated by Post-Amputation Sequential Accelerated Doxorubicin and Carboplatin Chemotherapy: 38 Cases.
Journal of the American Animal Hospital Association · 2016 · Australia
This study looked at 38 dogs with a type of bone cancer called appendicular osteosarcoma, which is a serious issue in veterinary medicine. The dogs had their affected limb amputated and then received a special chemotherapy treatment that was given more frequently than usual, but still expected to be safe. The average survival time for these dogs was about 317 days, with around
- Use of single-agent carboplatin as adjuvant or neoadjuvant therapy in conjunction with amputation for appendicular osteosarcoma in dogs.
Journal of the American Animal Hospital Association · 2009 · United States
This study looked at how well dogs with appendicular osteosarcoma (a type of bone cancer) do after having their leg amputated and receiving a drug called carboplatin. The researchers reviewed records from 155 dogs treated at 14 different veterinary centers. They found that, on average, dogs lived about 307 days after treatment and had a disease-free period of about 256 days bef
Frequently asked questions
- How fast does osteosarcoma spread?
- Micrometastasis is usually present at diagnosis even when chest x-rays look clean. That's why chemotherapy after amputation more than doubles median survival — it targets the micrometastatic disease.
- Can older dogs tolerate amputation?
- Almost always yes. The pain of osteosarcoma is severe; most dogs are much more comfortable in the first week after amputation than they were before. Excellent quality of life on three legs is the rule, not the exception.
- Are there alternatives to amputation?
- Limb-sparing surgery and stereotactic radiation therapy (SRT) are options in selected cases, often at university or large referral centres. Both can give good pain control while preserving the limb. Palliative bisphosphonates (e.g. zoledronate) plus pain control is another option for owners who decline surgery.